Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


MHLW Approves Abbott’s Humira To Be Distributed By Eisai In Japan

This article was originally published in PharmAsia News

Executive Summary

TOKYO - In contrast to wide criticisms about long drug lags in Japan, the Ministry of Health, Labor and Welfare has approved Abbott's rheumatoid arthritis antibody drug Humira (adalimumab) to be distributed by Eisai in Japan, the two companies announced June 17

You may also be interested in...

Eisai Posts First Ever Net Loss Due To Heavy Investment

TOKYO - Eisai posted losses in net income for fiscal 2007 due to heavy investment in oncology research and development through recent acquisitions. Eisai's losses were a first since it became a listed company in 1961

Eisai Strengthens Oncology Position With $3.9 Billion MGI Pharma Acquisition

In a move that will bolster its position in oncology, Eisai will buy MGI Pharma in an all-cash deal valued at $3.9 billion, the firms announced Dec. 10

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts